CTI BioPharma Corp
CTIC
Market Cap$1.2B
Close$
$9.82
8% upside
Current Fair Value
8% upsideUndervalued by 8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.20 Billion |
|---|---|
| Enterprise Value | $1.22 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.79 |
| Beta | 0.83 |
| Outstanding Shares | 131,566,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -11.46 |
|---|---|
| PEG | 27.69 |
| Price to Sales | - |
| Price to Book Ratio | -9.1 |
| Enterprise Value to Revenue | 16.16 |
| Enterprise Value to EBIT | -22.7 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -1.93 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About CTI BioPharma Corp
CEO: Adam Craig CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers...